Victory Square Technologies, a major shareholder in Hydreight Technologies, updated shareholders after the FDA Pharmacy Compounding Advisory Committee recommended six peptide-related bulk drug substances for inclusion on the Section 503A Bulks List. These substances include BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon, while Emideltide was not recommended. The recommendations are non-binding and FDA will decide on final inclusion. Victory Square's healthcare portfolio includes digital health platforms like Hydreight and biotech firms such as Insu Therapeutics, which develops peptide drug delivery technology. The company plans a shareholder webinar on August 5 to discuss developments in its investments.
